Active	Status	Sponsor type	Region	Phase	Filter
60 Active 1 Inactive 61 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hormigo, Adilia
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
NCT03223103: Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma	Active, not recruiting	1	13	US	Poly-ICLC, Hiltonol®, Tumor Treating Fields, Optune®, Peptides, Personalized peptides	Albert Einstein College of Medicine, NovoCure Ltd.	Glioblastoma	07/20	05/25
Weintraub, Lauren R
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
NCT04617002: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas	Available	N/A		US	ONC201 (dordaviprone)	Chimerix	Glioma, H3 K27M